Promis Neurosciences Inc (PMN)

$0.42 -0.01 (-2.85%)
Market Cap 14.13M
Revenue (ttm) 0.00
Net Income (ttm) 2.78M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 103,918
Avg Vol 50,184
Day's Range N/A - N/A
Shares Out 32.69M
Stochastic %K 0%
Beta -0.10
Analysts Strong Sell
Price Target $5.67

Company Profile

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer'...

Industry: Biotechnology
Sector: Healthcare
Phone: 416 847 6898
Fax: 416 847 6899
Address:
1920 Yonge Street, Suite 200, Toronto, Canada
ridethewaves3
ridethewaves3 Jul. 2 at 8:10 PM
$PMN they need to stop this bleeding fam. Been holding the bag for a while now.
0 · Reply
Stockttwits619
Stockttwits619 Jul. 2 at 7:03 PM
$PMN Might redo yesterday’s AH …WILL JUMP IN @ 2 59 if she spikes
0 · Reply
Sunny3999
Sunny3999 Jun. 25 at 5:12 PM
$PMN hope for double digits with excellent news
0 · Reply
BKLYN_Bull
BKLYN_Bull Jun. 14 at 8:58 PM
$PMN I’m wondering what everyone’s PT is after potential positive news?
2 · Reply
Sunny3999
Sunny3999 Jun. 10 at 12:18 PM
$PMN time to fly 🛫🔥🚀 Promis Neuroscience $GILD $JNJ $PFE $RHHBY
0 · Reply
Sunny3999
Sunny3999 Jun. 10 at 12:15 PM
$PMN ready to fly 🛫🔥 $ABBV $BMY $MRK $SNY
0 · Reply
Sunny3999
Sunny3999 Jun. 4 at 4:36 PM
ProMIS Neurosciences $PMN reached a major milestone with the initiation of our 100-patient Phase 1b clinical trial for PMN310, our lead antibody candidate for AD," said Neil Warma, CEO. $ABBV $BMY $MRK $SNY
0 · Reply
Sunny3999
Sunny3999 Jun. 4 at 4:36 PM
$PMN ProMIS Neurosciences reached a major milestone with the initiation of our 100-patient Phase 1b clinical trial for PMN310, our lead antibody candidate for AD," said Neil Warma, CEO. $GILD $JNJ $PFE $RHHBY
0 · Reply
Sunny3999
Sunny3999 Jun. 4 at 4:19 PM
$PMN June we will know about the biomarker levels, if the study isn’t stopped, this stock rockets 🚀 $SNY $ABBV $MRK $BMY
0 · Reply
Sunny3999
Sunny3999 Jun. 4 at 4:14 PM
$PMN In june we will know about the biomarker levels, if the study isn’t stopped, this stock rocket 🚀 $JNJ $PFE $RHHBY $GILD
0 · Reply
Latest News on PMN
ProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Jun 17, 2025, 7:00 AM EDT - 20 days ago

ProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

ProMIS Neurosciences Announces First Quarter 2025 Financial Results

May 12, 2025, 7:30 AM EDT - 2 months ago

ProMIS Neurosciences Announces First Quarter 2025 Financial Results

ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights

Mar 31, 2025, 7:00 AM EDT - 3 months ago

ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights

ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer's Disease/Parkinson's Disease 2025 International Conference

Mar 24, 2025, 7:00 AM EDT - 3 months ago

ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer's Disease/Parkinson's Disease 2025 International Conference

ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting

Mar 13, 2025, 7:00 AM EDT - 4 months ago

ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting

ProMIS Neurosciences to Participate in the 37th Annual Roth Conference

Mar 11, 2025, 7:30 AM EDT - 4 months ago

ProMIS Neurosciences to Participate in the 37th Annual Roth Conference

ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer's Disease

Feb 25, 2025, 7:00 AM EST - 4 months ago

ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer's Disease

ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference

Jan 29, 2025, 7:30 AM EST - 5 months ago

ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference

ProMIS Neurosciences Issues Letter to Shareholders

Jan 13, 2025, 10:30 AM EST - 6 months ago

ProMIS Neurosciences Issues Letter to Shareholders

ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights

Nov 14, 2024, 9:15 AM EST - 8 months ago

ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights

ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer's Disease Conference

Oct 30, 2024, 8:00 AM EDT - 8 months ago

ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer's Disease Conference

ProMIS Neurosciences to Showcase PMN310's Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences

Sep 12, 2024, 7:00 AM EDT - 10 months ago

ProMIS Neurosciences to Showcase PMN310's Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences

ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 5, 2024, 7:00 AM EDT - 10 months ago

ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024

Aug 1, 2024, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024

ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer's Association International Conference

Jul 30, 2024, 8:30 AM EDT - 1 year ago

ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer's Association International Conference

ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial

Jul 26, 2024, 8:35 AM EDT - 1 year ago

ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial

ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing

Jul 26, 2024, 8:30 AM EDT - 1 year ago

ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing

ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights

May 14, 2024, 4:01 PM EDT - 1 year ago

ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights

ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies

Apr 30, 2024, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies

ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS

Apr 9, 2024, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS

ProMIS Neurosciences to Present in Upcoming Investor Conferences in April

Apr 4, 2024, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences to Present in Upcoming Investor Conferences in April

ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights

Apr 1, 2024, 4:15 PM EDT - 1 year ago

ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights

ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio

Mar 11, 2024, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio

ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference

Feb 22, 2024, 7:00 AM EST - 1 year ago

ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference

ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine

Jan 22, 2024, 7:00 AM EST - 1 year ago

ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine

ProMIS Neurosciences, Inc. Announces Leadership Transition

Jan 3, 2024, 7:00 AM EST - 1 year ago

ProMIS Neurosciences, Inc. Announces Leadership Transition

ProMIS Neurosciences Announces Publication on Novel Target for ALS

Dec 20, 2023, 7:00 AM EST - 1 year ago

ProMIS Neurosciences Announces Publication on Novel Target for ALS

ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer's Disease

Nov 20, 2023, 7:00 AM EST - 1 year ago

ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer's Disease

ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights

Nov 14, 2023, 4:30 PM EST - 1 year ago

ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights

ProMIS Neurosciences Closes $20.4 Million Private Placement Financing

Sep 8, 2023, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences Closes $20.4 Million Private Placement Financing

ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Sep 6, 2023, 12:18 PM EDT - 1 year ago

ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference

ProMIS Neurosciences Announces $20.4 Million Private Placement Financing

Aug 21, 2023, 4:12 PM EDT - 2 years ago

ProMIS Neurosciences Announces $20.4 Million Private Placement Financing

ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights

Aug 14, 2023, 5:33 PM EDT - 2 years ago

ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights

ProMIS Showcases Preclinical Data at the Alzheimer's Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimer's Pipeline

Jul 17, 2023, 7:00 AM EDT - 2 years ago

ProMIS Showcases Preclinical Data at the Alzheimer's Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimer's Pipeline

ProMIS Announces Completion of Continuance

Jul 14, 2023, 7:45 AM EDT - 2 years ago

ProMIS Announces Completion of Continuance

ProMIS Neurosciences to Consolidate Trading on the Nasdaq Exchange

Jul 10, 2023, 7:55 AM EDT - 2 years ago

ProMIS Neurosciences to Consolidate Trading on the Nasdaq Exchange

ProMIS Neurosciences Holds Annual Meeting of Shareholders All Resolutions Approved

Jun 30, 2023, 8:00 AM EDT - 2 years ago

ProMIS Neurosciences Holds Annual Meeting of Shareholders All Resolutions Approved

CORRECTION: Updated URL to Access ProMIS Annual Meeting of Shareholders on June 29, 2023 at 9:30am Eastern Time

Jun 29, 2023, 8:00 AM EDT - 2 years ago

CORRECTION: Updated URL to Access ProMIS Annual Meeting of Shareholders on June 29, 2023 at 9:30am Eastern Time

ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlights

May 15, 2023, 5:00 PM EDT - 2 years ago

ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlights

ProMIS Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimer's Disease

May 8, 2023, 9:00 AM EDT - 2 years ago

ProMIS Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimer's Disease

Data Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimer's Disease

Apr 25, 2023, 5:00 PM EDT - 2 years ago

Data Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimer's Disease

ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer's Disease and ALS at American Academy of Neurology Annual Meeting

Apr 24, 2023, 7:30 AM EDT - 2 years ago

ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer's Disease and ALS at American Academy of Neurology Annual Meeting

ProMIS Neurosciences Announces Submission of Investigational New Drug (IND) Application for Lead Antibody PMN310

Apr 10, 2023, 7:30 AM EDT - 2 years ago

ProMIS Neurosciences Announces Submission of Investigational New Drug (IND) Application for Lead Antibody PMN310

Lead Therapeutic Candidate, PMN310, Demonstrates Enhanced Selectivity for Toxic Oligomers Compared to Other Amyloid-Beta-Directed Antibodies in Poster Presentation at AD/PD 2023

Mar 29, 2023, 8:30 AM EDT - 2 years ago

Lead Therapeutic Candidate, PMN310, Demonstrates Enhanced Selectivity for Toxic Oligomers Compared to Other Amyloid-Beta-Directed Antibodies in Poster Presentation at AD/PD 2023

ProMIS Neurosciences Announces Abstracts Accepted for Presentation at the American Academy of Neurology 2023 Annual Meeting

Mar 13, 2023, 9:00 AM EDT - 2 years ago

ProMIS Neurosciences Announces Abstracts Accepted for Presentation at the American Academy of Neurology 2023 Annual Meeting

ProMIS Neurosciences to Present New Preclinical Data for PMN310 at AD/PD 2023

Mar 13, 2023, 7:00 AM EDT - 2 years ago

ProMIS Neurosciences to Present New Preclinical Data for PMN310 at AD/PD 2023

ProMIS Neurosciences Announces Full Year 2022 Financial Results and Recent Highlights

Mar 8, 2023, 5:06 PM EST - 2 years ago

ProMIS Neurosciences Announces Full Year 2022 Financial Results and Recent Highlights

Promis Neurosciences to Present at the Oppenheimer 33rd Annual Healthcare Conference

Mar 8, 2023, 7:00 AM EST - 2 years ago

Promis Neurosciences to Present at the Oppenheimer 33rd Annual Healthcare Conference

ProMIS Neurosciences Announces Third Quarter 2022 Financial Results and Recent Highlights

Nov 14, 2022, 7:00 AM EST - 2 years ago

ProMIS Neurosciences Announces Third Quarter 2022 Financial Results and Recent Highlights

ValenzaBio Announces Positive Preliminary Data from Phase 1b/2a Trial of VB119, an Anti-CD19 Monoclonal Antibody for the Treatment of Primary Membranous Nephropathy

Nov 3, 2022, 10:00 AM EDT - 2 years ago

ValenzaBio Announces Positive Preliminary Data from Phase 1b/2a Trial of VB119, an Anti-CD19 Monoclonal Antibody for the Treatment of Primary Membranous Nephropathy

ridethewaves3
ridethewaves3 Jul. 2 at 8:10 PM
$PMN they need to stop this bleeding fam. Been holding the bag for a while now.
0 · Reply
Stockttwits619
Stockttwits619 Jul. 2 at 7:03 PM
$PMN Might redo yesterday’s AH …WILL JUMP IN @ 2 59 if she spikes
0 · Reply
Sunny3999
Sunny3999 Jun. 25 at 5:12 PM
$PMN hope for double digits with excellent news
0 · Reply
BKLYN_Bull
BKLYN_Bull Jun. 14 at 8:58 PM
$PMN I’m wondering what everyone’s PT is after potential positive news?
2 · Reply
Sunny3999
Sunny3999 Jun. 10 at 12:18 PM
$PMN time to fly 🛫🔥🚀 Promis Neuroscience $GILD $JNJ $PFE $RHHBY
0 · Reply
Sunny3999
Sunny3999 Jun. 10 at 12:15 PM
$PMN ready to fly 🛫🔥 $ABBV $BMY $MRK $SNY
0 · Reply
Sunny3999
Sunny3999 Jun. 4 at 4:36 PM
ProMIS Neurosciences $PMN reached a major milestone with the initiation of our 100-patient Phase 1b clinical trial for PMN310, our lead antibody candidate for AD," said Neil Warma, CEO. $ABBV $BMY $MRK $SNY
0 · Reply
Sunny3999
Sunny3999 Jun. 4 at 4:36 PM
$PMN ProMIS Neurosciences reached a major milestone with the initiation of our 100-patient Phase 1b clinical trial for PMN310, our lead antibody candidate for AD," said Neil Warma, CEO. $GILD $JNJ $PFE $RHHBY
0 · Reply
Sunny3999
Sunny3999 Jun. 4 at 4:19 PM
$PMN June we will know about the biomarker levels, if the study isn’t stopped, this stock rockets 🚀 $SNY $ABBV $MRK $BMY
0 · Reply
Sunny3999
Sunny3999 Jun. 4 at 4:14 PM
$PMN In june we will know about the biomarker levels, if the study isn’t stopped, this stock rocket 🚀 $JNJ $PFE $RHHBY $GILD
0 · Reply
Glopolon
Glopolon Jun. 1 at 2:03 PM
$PMN Expecting interim analysis soon, but they use up a lot of cash. Will need good data, and probably then another raise.
1 · Reply
Sunny3999
Sunny3999 May. 19 at 5:20 PM
$PMN buying as much as I can! Soon it should reverse up to several $
1 · Reply
JarvisFlow
JarvisFlow May. 12 at 12:30 PM
Maxim Group has adjusted their stance on ProMIS Neurosciences ( $PMN ), setting the rating to Buy with a target price of 3.
1 · Reply
Alex1710
Alex1710 May. 8 at 9:26 PM
$PMN The end is near. In a year from now at most it won't exist.
3 · Reply
Alex1710
Alex1710 May. 8 at 1:22 AM
$PMN Pure scrap.
1 · Reply
WAYWARD_SUN
WAYWARD_SUN May. 6 at 2:32 PM
$PMN .
1 · Reply
7DAYSDIMENSIONS
7DAYSDIMENSIONS May. 1 at 6:48 PM
$PMN Honestly I don't understand people selling at 0.64. Something has to be wrong in their head.
2 · Reply
WAYWARD_SUN
WAYWARD_SUN Apr. 25 at 1:54 PM
$PMN
0 · Reply
Tigger456
Tigger456 Apr. 21 at 2:45 PM
$PMN For anyone who has a family member or knows someone who is or has suffered from Alzheimer’s, supporting innovative research is the only route to solving it. This company needs more eyes. They’re doing something different and may have a solution.
0 · Reply
7DAYSDIMENSIONS
7DAYSDIMENSIONS Apr. 17 at 4:42 PM
$PMN something cooking?
1 · Reply
Stockttwits619
Stockttwits619 Apr. 15 at 8:24 PM
$DMN $STKH $XHG $PMN $STKH
1 · Reply
JarvisFlow
JarvisFlow Apr. 1 at 2:56 PM
Guggenheim has updated their rating for ProMIS Neurosciences ( $PMN ) to Buy with a price target of 6.
0 · Reply